Beijing SL Pharmaceutical Co Ltd

SHE:002038 China Drug Manufacturers - Specialty & Generic
Market Cap
$856.91 Million
CN¥6.29 Billion CNY
Market Cap Rank
#10046 Global
#2158 in China
Share Price
CN¥6.12
Change (1 day)
-0.81%
52-Week Range
CN¥6.07 - CN¥8.61
All Time High
CN¥10151.79
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more

Beijing SL Pharmaceutical Co Ltd (002038) - Net Assets

Latest net assets as of September 2025: CN¥5.70 Billion CNY

Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has net assets worth CN¥5.70 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.03 Billion) and total liabilities (CN¥327.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥5.70 Billion
% of Total Assets 94.56%
Annual Growth Rate 21.26%
5-Year Change 11.95%
10-Year Change 54.45%
Growth Volatility 42.07

Beijing SL Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Beijing SL Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Beijing SL Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Beijing SL Pharmaceutical Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥5.58 Billion -3.95%
2023-12-31 CN¥5.81 Billion +6.04%
2022-12-31 CN¥5.48 Billion +2.87%
2021-12-31 CN¥5.33 Billion +6.85%
2020-12-31 CN¥4.98 Billion +3.39%
2019-12-31 CN¥4.82 Billion +6.70%
2018-12-31 CN¥4.52 Billion +5.10%
2017-12-31 CN¥4.30 Billion +9.40%
2016-12-31 CN¥3.93 Billion +8.77%
2015-12-31 CN¥3.61 Billion +13.58%
2014-12-31 CN¥3.18 Billion +22.87%
2013-12-31 CN¥2.59 Billion +22.61%
2012-12-31 CN¥2.11 Billion +25.27%
2011-12-31 CN¥1.69 Billion +39.15%
2010-12-31 CN¥1.21 Billion +23.22%
2009-12-31 CN¥983.06 Million +28.91%
2008-12-31 CN¥762.61 Million +38.17%
2007-12-31 CN¥551.93 Million +29.50%
2006-12-31 CN¥426.20 Million +11.43%
2005-12-31 CN¥382.49 Million +5.82%
2004-12-31 CN¥361.45 Million +214.17%
2003-12-31 CN¥115.05 Million +34.39%
2002-12-31 CN¥85.61 Million +29.14%
2001-12-31 CN¥66.29 Million --

Equity Component Analysis

This analysis shows how different components contribute to Beijing SL Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 17965.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.85 Billion 69.08%
Common Stock CN¥1.03 Billion 18.44%
Other Comprehensive Income CN¥695.07 Million 12.47%
Other Components CN¥430.42K 0.01%
Total Equity CN¥5.57 Billion 100.00%

Beijing SL Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Bit Digital Inc
NASDAQ:BTBT
 		$524.35 Million
VP Bank AG
SW:VPBN
 		$524.54 Million
Wafer Works
TWO:6182
 		$524.54 Million
Intellian Technologies Inc
KQ:189300
 		$524.59 Million
Green Dot Corporation
NYSE:GDOT
 		$524.22 Million
Resolute Holdings Management, Inc.
NYSE:RHLD
 		$524.16 Million
Northfield Bancorp Inc
NASDAQ:NFBK
 		$523.97 Million
ASSET WORLD CORP PCL-NVDR
BK:AWC-R
 		$523.94 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Beijing SL Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,800,616,100 to 5,572,447,942, a change of -228,168,158 (-3.9%).
  • Net loss of 74,065,656 reduced equity.
  • Dividend payments of 154,102,500 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-74.07 Million -1.33%
Dividends Paid CN¥154.10 Million -2.77%
Other Changes CN¥-2.00 -0.0%
Total Change CN¥- -3.93%

Book Value vs Market Value Analysis

This analysis compares Beijing SL Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.16x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 94.84x to 1.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.06 CN¥6.12 x
2002-12-31 CN¥0.08 CN¥6.12 x
2003-12-31 CN¥0.11 CN¥6.12 x
2004-12-31 CN¥0.53 CN¥6.12 x
2005-12-31 CN¥0.38 CN¥6.12 x
2006-12-31 CN¥0.63 CN¥6.12 x
2007-12-31 CN¥0.54 CN¥6.12 x
2008-12-31 CN¥0.74 CN¥6.12 x
2009-12-31 CN¥0.95 CN¥6.12 x
2010-12-31 CN¥1.16 CN¥6.12 x
2011-12-31 CN¥1.59 CN¥6.12 x
2012-12-31 CN¥1.98 CN¥6.12 x
2013-12-31 CN¥2.49 CN¥6.12 x
2014-12-31 CN¥3.06 CN¥6.12 x
2015-12-31 CN¥3.48 CN¥6.12 x
2016-12-31 CN¥3.79 CN¥6.12 x
2017-12-31 CN¥4.16 CN¥6.12 x
2018-12-31 CN¥6.57 CN¥6.12 x
2019-12-31 CN¥4.64 CN¥6.12 x
2020-12-31 CN¥4.84 CN¥6.12 x
2021-12-31 CN¥5.17 CN¥6.12 x
2022-12-31 CN¥5.32 CN¥6.12 x
2023-12-31 CN¥5.71 CN¥6.12 x
2024-12-31 CN¥5.27 CN¥6.12 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Beijing SL Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -1.33%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -11.21%
  • • Asset Turnover: 0.11x
  • • Equity Multiplier: 1.07x
  • Recent ROE (-1.33%) is below the historical average (16.56%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 28.52% 58.74% 0.42x 1.16x CN¥12.28 Million
2002 22.54% 38.66% 0.49x 1.20x CN¥10.73 Million
2003 27.14% 43.91% 0.47x 1.32x CN¥19.70 Million
2004 8.86% 34.39% 0.24x 1.08x CN¥-4.13 Million
2005 8.86% 28.53% 0.29x 1.06x CN¥-4.37 Million
2006 11.24% 33.24% 0.31x 1.08x CN¥5.30 Million
2007 24.45% 56.75% 0.40x 1.06x CN¥79.67 Million
2008 28.65% 60.85% 0.45x 1.04x CN¥141.82 Million
2009 25.28% 62.59% 0.38x 1.06x CN¥147.55 Million
2010 22.90% 59.57% 0.37x 1.05x CN¥153.64 Million
2011 32.23% 84.03% 0.36x 1.07x CN¥360.95 Million
2012 23.58% 47.77% 0.45x 1.09x CN¥277.00 Million
2013 22.50% 49.70% 0.43x 1.06x CN¥320.83 Million
2014 22.08% 55.92% 0.37x 1.05x CN¥380.29 Million
2015 16.07% 49.72% 0.31x 1.05x CN¥217.26 Million
2016 11.60% 44.77% 0.25x 1.05x CN¥62.46 Million
2017 12.49% 42.96% 0.27x 1.07x CN¥106.51 Million
2018 12.70% 26.36% 0.43x 1.11x CN¥121.66 Million
2019 10.12% 23.98% 0.39x 1.09x CN¥5.96 Million
2020 7.33% 32.78% 0.21x 1.08x CN¥-132.75 Million
2021 8.02% 35.06% 0.21x 1.08x CN¥-105.21 Million
2022 4.29% 22.32% 0.18x 1.07x CN¥-312.40 Million
2023 7.18% 40.92% 0.16x 1.08x CN¥-163.37 Million
2024 -1.33% -11.21% 0.11x 1.07x CN¥-631.31 Million

Industry Comparison

This section compares Beijing SL Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Beijing SL Pharmaceutical Co Ltd (002038) CN¥5.70 Billion 28.52% 0.06x $524.29 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million